CoLucid Pharmaceuticals issued a $74.8 million underwritten public offering of common stock in September 2016. The offering featured more than 3.7 million shares of common stock sold at a public offering price of $20 per share. Our firm represented CoLucid in the transaction, which follows the company's 2015 IPO.
September 2016